Kolexia
Velten Michel
Santé publique
Centre Paul Strauss
Strasbourg, France
156 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs du poumon Seconde tumeur primitive Tumeurs de la prostate Carcinomes Tumeurs de la tête et du cou Métastase tumorale Tumeurs du col de l'utérus Fatigue

Industries

Roche
1 collaboration(s)
Dernière en 2016
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC): Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Lung Cancer in France Since 2015
Essai Clinique (BMS)   15 décembre 2023
Refining Incidence and Characteristics of Inflammatory Myopathies: A Quadruple-Source Capture-Recapture Survey Using the 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria.
Arthritis & rheumatology (Hoboken, N.J.)   04 août 2023
ESME-MBC: Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Metastatic Breast Cancer Across the French Comprehensive Cancer Centers From 2008
Essai Clinique (Seagen)   16 mars 2023
Trends in incidence of invasive vaginal cancer in France from 1990 to 2018 and survival of recently diagnosed women - A population-based study.
European journal of obstetrics, gynecology, and reproductive biology   13 février 2023
Laryngeal dysfunction is prominent in asthmatic women treated by inhaled corticosteroids.
Clinical and translational allergy   03 janvier 2023
Consequences of Discontinuing a 4/6 Cyclin D-Dependent Kinase Inhibitor During Endocrine Treatment in Hormone-Sensitive Metastatic Breast Cancer Patients in the Context of the COVID-19 Outbreak.
Clinical breast cancer   13 octobre 2022
Utility values and its time to deterioration in breast cancer patients after diagnosis and during treatments.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation   19 mai 2022
Analysis and Breakdown of Overall 1-Year Costs Relative to Inpatient and Outpatient Care Among Rheumatoid Arthritis Patients Treated with Biotherapies Using Health Insurance Claims Database in Alsace.
Drugs - real world outcomes   08 avril 2022
Incidence and Trend of Type I and II Endometrial Cancer in Women from Two Population-Based European Cancer Registries (1998-2012).
International journal of environmental research and public health   23 mars 2022
Abstract P1-17-07: Consequences of stopping a 4/6 cyclin D-dependent kinase Inhibitor in metastatic breast cancer patients with clinical benefit on endocrine treatment, in the context of the COVID-19 outbreak
2021 San Antonio Breast Cancer Symposium   15 février 2022